Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Tempest Therapeutics
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
August 21, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
August 15, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
June 20, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
June 18, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest to Participate in Upcoming Investor Conferences
May 21, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
April 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
April 04, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Year End 2023 Financial Results and Provides Business Update
March 19, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
March 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
March 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
February 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Adopts Limited Duration Stockholder Rights Plan
October 11, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
October 11, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
October 10, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
September 19, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
July 19, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest to Present at the Jefferies Global Healthcare Conference
May 31, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
May 25, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 19, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tickers
TPST
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.